Arcus grabs US rights to a WuXi-built PD-1 as second wave of checkpoints builds
West Coast upstart Arcus Biosciences has bagged its very own PD-1 antibody to take into the clinic with its immuno-oncology pipeline drugs.
Arcus turned to WuXi Biologics and its Chinese partner Harbin Gloria Pharmaceuticals for regional North American, European and Japanese rights to GLS-010. The US biotech is paying $18.5 million upfront along with a potential motherload of development and sales milestones amounting to $816 million.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.